Aligos Therapeutics Reports $30.6M Revenue and $1.5M Net Loss for Q2 2026

Aligos Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded total revenue of $30.6 million, a substantial increase from $1.3 million in the same period last year, primarily driven by a $27.8 million revenue recognition from a licensing agreement with Xiamen Amoytop Biotech Co., Ltd. This agreement, which includes an upfront payment and potential milestone payments, marks a pivotal shift in Aligos's revenue generation strategy, as the company had no licensing revenue in the previous year. However, customer revenue fell to zero from $965,000, reflecting the completion of prior contractual obligations.

Operating expenses for the second quarter of 2026 totaled $29.7 million, up 52% from $19.5 million in the same quarter of 2025. This increase was largely attributed to a 72% rise in research and development expenses, which reached $24.1 million, as the company intensified its clinical development activities, particularly for its lead drug candidate, pevifoscorvir sodium. General and administrative expenses remained relatively stable, increasing only slightly to $5.6 million. The net loss for the quarter was $1.5 million, a significant improvement compared to a loss of $15.9 million in the prior year, indicating a 91% reduction in losses.

In terms of operational metrics, Aligos's total assets decreased to $66.3 million from $88.5 million at the end of 2025, primarily due to a reduction in cash and cash equivalents, which increased to $30.4 million from $18.3 million. The company’s accumulated deficit also grew to $666.7 million, reflecting ongoing investments in research and development. The headcount remained stable, with no significant changes reported in staffing levels.

Looking ahead, Aligos anticipates continued investment in its clinical programs, particularly for pevifoscorvir sodium, which has received Fast Track and Breakthrough Therapy designations from regulatory authorities. The company plans to raise additional capital to support its operations beyond the fourth quarter of 2026, as it faces substantial doubt regarding its ability to continue as a going concern without further funding. Aligos is exploring various financing options, including public or private equity offerings and strategic collaborations, to ensure the continuation of its development programs and operational activities.